Terms: = Prostate cancer AND GATA2, NFE1B, 2624, ENSG00000179348, MGC2306, P23769
52 results:
1. Androgen Receptor-Interacting Proteins in prostate cancer Development and Therapy Resistance.
Culig Z; Puhr M
Am J Pathol; 2024 Mar; 194(3):324-334. PubMed ID: 38104650
[TBL] [Abstract] [Full Text] [Related]
2. Development of machine learning prognostic models for overall survival of prostate cancer patients with lymph node-positive.
Peng ZH; Tian JH; Chen BH; Zhou HB; Bi H; He MX; Li MR; Zheng XY; Wang YW; Chong T; Li ZL
Sci Rep; 2023 Oct; 13(1):18424. PubMed ID: 37891423
[TBL] [Abstract] [Full Text] [Related]
3. gata2 co-opts TGFβ1/SMAD4 oncogenic signaling and inherited variants at 6q22 to modulate prostate cancer progression.
Yang X; Zhang Q; Li S; Devarajan R; Luo B; Tan Z; Wang Z; Giannareas N; Wenta T; Ma W; Li Y; Yang Y; Manninen A; Wu S; Wei GH
J Exp Clin Cancer Res; 2023 Aug; 42(1):198. PubMed ID: 37550764
[TBL] [Abstract] [Full Text] [Related]
4. A gata2-CDC6 axis modulates androgen receptor blockade-induced senescence in prostate cancer.
Mourkioti I; Polyzou A; Veroutis D; Theocharous G; Lagopati N; Gentile E; Stravokefalou V; Thanos DF; Havaki S; Kletsas D; Panaretakis T; Logothetis CJ; Stellas D; Petty R; Blandino G; Papaspyropoulos A; Gorgoulis VG
J Exp Clin Cancer Res; 2023 Jul; 42(1):187. PubMed ID: 37507762
[TBL] [Abstract] [Full Text] [Related]
5. Nucleosome Patterns in Circulating Tumor DNA Reveal Transcriptional Regulation of Advanced prostate cancer Phenotypes.
De Sarkar N; Patton RD; Doebley AL; Hanratty B; Adil M; Kreitzman AJ; Sarthy JF; Ko M; Brahma S; Meers MP; Janssens DH; Ang LS; Coleman IM; Bose A; Dumpit RF; Lucas JM; Nunez TA; Nguyen HM; McClure HM; Pritchard CC; Schweizer MT; Morrissey C; Choudhury AD; Baca SC; Berchuck JE; Freedman ML; Ahmad K; Haffner MC; Montgomery RB; Corey E; Henikoff S; Nelson PS; Ha G
Cancer Discov; 2023 Mar; 13(3):632-653. PubMed ID: 36399432
[TBL] [Abstract] [Full Text] [Related]
6. A COP1-gata2 axis suppresses AR signaling and prostate cancer.
Shen T; Dong B; Meng Y; Moore DD; Yang F
Proc Natl Acad Sci U S A; 2022 Oct; 119(43):e2205350119. PubMed ID: 36251994
[TBL] [Abstract] [Full Text] [Related]
7. Dynamic nucleosome landscape elicits a noncanonical gata2 pioneer model.
Li T; Liu Q; Chen Z; Fang K; Huang F; Fu X; Wang Q; Jin VX
Nat Commun; 2022 Jun; 13(1):3145. PubMed ID: 35672415
[TBL] [Abstract] [Full Text] [Related]
8. Inhibiting 3βHSD1 to eliminate the oncogenic effects of progesterone in prostate cancer.
Hou Z; Huang S; Mei Z; Chen L; Guo J; Gao Y; Zhuang Q; Zhang X; Tan Q; Yang T; Liu Y; Chi Y; Qi L; Jiang T; Shao X; Wu Y; Xu X; Qin J; Ren R; Tang H; Wu D; Li Z
Cell Rep Med; 2022 Mar; 3(3):100561. PubMed ID: 35492874
[TBL] [Abstract] [Full Text] [Related]
9. Inhibition of gata2 in prostate cancer by a clinically available small molecule.
Kaochar S; Rusin A; Foley C; Rajapakshe K; Robertson M; Skapura D; Mason C; Berman De Ruiz K; Tyryshkin AM; Deng J; Shin JN; Fiskus W; Dong J; Huang S; Navone NM; Davis CM; Ehli EA; Coarfa C; Mitsiades N
Endocr Relat Cancer; 2021 Nov; 29(1):15-31. PubMed ID: 34636746
[TBL] [Abstract] [Full Text] [Related]
10. MAPK4 promotes prostate cancer by concerted activation of androgen receptor and AKT.
Shen T; Wang W; Zhou W; Coleman I; Cai Q; Dong B; Ittmann MM; Creighton CJ; Bian Y; Meng Y; Rowley DR; Nelson PS; Moore DD; Yang F
J Clin Invest; 2021 Feb; 131(4):. PubMed ID: 33586682
[TBL] [Abstract] [Full Text] [Related]
11. Anti-S100A4 Antibody Therapy Is Efficient in Treating Aggressive prostate cancer and Reversing Immunosuppression: Serum and Biopsy
Ganaie AA; Mansini AP; Hussain T; Rao A; Siddique HR; Shabaneh A; Ferrari MG; Murugan P; Klingelhöfer J; Wang J; Ambartsumian N; Warlick CA; Konety BR; Saleem M
Mol Cancer Ther; 2020 Dec; 19(12):2598-2611. PubMed ID: 32999046
[TBL] [Abstract] [Full Text] [Related]
12. LINC00675 activates androgen receptor axis signaling pathway to promote castration-resistant prostate cancer progression.
Yao M; Shi X; Li Y; Xiao Y; Butler W; Huang Y; Du L; Wu T; Bian X; Shi G; Ye D; Fu G; Wang J; Ren S
Cell Death Dis; 2020 Aug; 11(8):638. PubMed ID: 32801300
[TBL] [Abstract] [Full Text] [Related]
13. Urine Extracellular Vesicle gata2 mRNA Discriminates Biopsy Result in Men with Suspicion of prostate cancer.
Woo J; Santasusagna S; Banks J; Pastor-Lopez S; Yadav K; Carceles-Cordon M; Dominguez-Andres A; Den RB; Languino LR; Pippa R; Lallas CD; Lu-Yao G; Kelly WK; Knudsen KE; Rodriguez-Bravo V; Tewari AK; Prats JM; Leiby BE; Gomella LG; Domingo-Domenech J
J Urol; 2020 Oct; 204(4):691-700. PubMed ID: 32250729
[TBL] [Abstract] [Full Text] [Related]
14. Cellular rewiring in lethal prostate cancer: the architect of drug resistance.
Carceles-Cordon M; Kelly WK; Gomella L; Knudsen KE; Rodriguez-Bravo V; Domingo-Domenech J
Nat Rev Urol; 2020 May; 17(5):292-307. PubMed ID: 32203305
[TBL] [Abstract] [Full Text] [Related]
15. Shaping Chromatin States in prostate cancer by Pioneer Transcription Factors.
Hankey W; Chen Z; Wang Q
Cancer Res; 2020 Jun; 80(12):2427-2436. PubMed ID: 32094298
[TBL] [Abstract] [Full Text] [Related]
16. 12 new susceptibility loci for prostate cancer identified by genome-wide association study in Japanese population.
Takata R; Takahashi A; Fujita M; Momozawa Y; Saunders EJ; Yamada H; Maejima K; Nakano K; Nishida Y; Hishida A; Matsuo K; Wakai K; Yamaji T; Sawada N; Iwasaki M; Tsugane S; Sasaki M; Shimizu A; Tanno K; Minegishi N; Suzuki K; Matsuda K; Kubo M; Inazawa J; Egawa S; Haiman CA; Ogawa O; Obara W; Kamatani Y; Akamatsu S; Nakagawa H
Nat Commun; 2019 Sep; 10(1):4422. PubMed ID: 31562322
[TBL] [Abstract] [Full Text] [Related]
17. Factors that influence the androgen receptor cistrome in benign and malignant prostate cells.
Copeland BT; Du J; Pal SK; Jones JO
Mol Oncol; 2019 Dec; 13(12):2616-2632. PubMed ID: 31520575
[TBL] [Abstract] [Full Text] [Related]
18. Molecular determinants for enzalutamide-induced transcription in prostate cancer.
Yuan F; Hankey W; Wu D; Wang H; Somarelli J; Armstrong AJ; Huang J; Chen Z; Wang Q
Nucleic Acids Res; 2019 Nov; 47(19):10104-10114. PubMed ID: 31501863
[TBL] [Abstract] [Full Text] [Related]
19. The independent prognostic impact of the gata2 pioneering factor is restricted to ERG-negative prostate cancer.
Büscheck F; Zub M; Heumann A; Hube-Magg C; Simon R; Lang DS; Höflmayer D; Neubauer E; Jacobsen F; Hinsch A; Luebke AM; Tsourlakis MC; Sauter G; Huland H; Graefen M; Haese A; Heinzer H; Schlomm T; Clauditz TS; Burandt E; Wilczak W; Steurer S; Minner S
Tumour Biol; 2019 Jul; 41(7):1010428318824815. PubMed ID: 31296150
[TBL] [Abstract] [Full Text] [Related]
20. Healthcare providers' discussions of physical activity with older survivors of cancer: Potential missed opportunities for health promotion.
Siembida EJ; Kent EE; Bellizzi KM; Smith AW
J Geriatr Oncol; 2020 Apr; 11(3):437-443. PubMed ID: 31122873
[TBL] [Abstract] [Full Text] [Related]
[Next]
